EpiCast Report: Supportive Care in Oncology – Epidemiology Forecast to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Cancer is a broad term for a group of diseases characterized by uncontrolled cell proliferation. Worldwide, it is estimated that 14 million new cases of cancer are diagnosed each year, and 30–50% of those cases are preventable (WHO, 2017). Cancer is the second leading cause of death worldwide, with more than eight million deaths caused by cancer in 2015 (WHO, 2017).
GlobalData epidemiologists provide the number of diagnosed incident cases of all cancer treated with chemotherapy and the number of diagnosed incident cases of chemotherapy-treated cancers that develop associated conditions (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia). GlobalData epidemiologists also provide the number of diagnosed incident cases of prostate, breast, and lung cancers, and those that progress to bone metastasis. To forecast the diagnosed incident and the five-year diagnosed prevalent cases of all cancer in the 7MM, GlobalData epidemiologists selected reputable international cancer databases and nationally representative, population-based studies that provided the diagnosed incidence or relative survival rates for all cancer in the 7MM.
In 2016, there were 933,412 diagnosed incident cases of all cancer receiving chemotherapy treatment in men and women, ages 18 years and older, in the 7MM. Combination therapy was more common, with 75.8% of cases receiving chemotherapy in conjunction with surgery, radiation, or both. The remaining cases, 24.2%, received chemotherapy alone. Of those receiving chemotherapy, anemia and nausea and vomiting were the most common conditions resulting from the treatment. In 2016, there were 809,204 cases of chemotherapy-induced anemia and 746,730 cases of chemotherapy-induced nausea and vomiting in the 7MM.

Scope

The Supportive Care in Oncology EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of supportive care in oncology in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of all cancer; five-year diagnosed prevalent cases of all cancer; diagnosed incident cases of all cancer treated with chemotherapy; diagnosed incident cases all cancer treated with chemotherapy with chemotherapy induced condition (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia); diagnosed incident cases of prostate cancer (men ages 35 years and older); diagnosed incident cases of breast cancer (women ages 20 years and older); diagnosed incident cases of lung cancer (men and women ages 20 years and older); diagnosed incident cases of prostate, breast, and lung cancer that metastasize to bone.

The supportive care in oncology epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Supportive Care in Oncology EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global oncology and chemotherapy treatment market.

Quantify patient populations in the global oncology and chemotherapy treatment market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chemotherapy induced conditions therapeutics in each of the markets covered.

Understand magnitude of chemotherapy induced conditions.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Supportive Care Oncology: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Global and Historical Trends

3.3 Forecast Methodology

3.3.1 Sources

3.3.2 Forecast Assumptions and Methods

3.4 Epidemiological Forecast for Supportive Care in Oncology (2016–2026)

3.4.1 Diagnosed Incident Cases of All Cancer

3.4.2 Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment

3.4.3 Diagnosed Incident Cases of Chemotherapy-Induced Conditions

3.4.4 Diagnosed Incident Cases of Prostate Cancer

3.4.5 Diagnosed Incident Cases of Prostate Cancer That Develop Bone Metastasis

3.4.6 Diagnosed Incident Cases of Breast Cancer

3.4.7 Diagnosed Incident Cases of Breast Cancer That Develop Bone Metastasis

3.4.8 Diagnosed Incident Cases of Lung Cancer

3.4.9 Diagnosed Incident Cases of Lung Cancer That Develop Bone Metastasis

3.4.10 Five-Year Diagnosed Prevalent Cases of All Cancer

3.5 Discussion

3.5.1 Epidemiological Forecast Insight

3.5.2 Limitations of Analysis

3.5.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologists

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: 7MM, Diagnosed Incident Cases of All Cancer, Men and Women, Ages ≥20 Years

Figures

Figure 1: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages ≥18

Years

Figure 2: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages ≥18 Years

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Men, Ages ≥18 Years, 2016–2026

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Women, Ages ≥18 Years, 2016–2026

Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of All Cancer

Figure 6: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of All Cancer

Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Prostate Cancer

Figure 8: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Breast Cancer

Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Lung Cancer

Figure 10: 7MM, Sources Used to Forecast Chemotherapy-Induced Conditions

Figure 11: 7MM, Sources Used to Forecast Bone Metastasis in Prostate, Breast, and Lung Cancer

Figure 12: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages ≥18 Years

Figure 13: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages ≥18 Years

Figure 14: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years

Figure 15: 7MM, Diagnosed Incident Cases of Prostate Cancer That Have Developed or Will Develop Bone Metastasis, Men, Ages ≥35 Years

Figure 16: 7MM, Diagnosed Incident Cases of Breast Cancer, Women, Ages ≥20 Years

Figure 17: 7MM, Diagnosed Incident Cases of Breast Cancer That Have Developed or Will Develop Bone Metastasis, Women, Ages ≥20 Years

Figure 18: 7MM, Diagnosed Incident Cases of Lung Cancer, Men and Women, Ages ≥20 Years

Figure 19: 7MM, Diagnosed Incident Cases of Lung Cancer That Have Developed or Will Develop Bone Metastasis, Men and Women, Ages ≥20 Years

Figure 20: 7MM, Five-Year Diagnosed Prevalent Cases of All Cancer, Men and Women, All Ages

Frequently asked questions

EpiCast Report: Supportive Care in Oncology – Epidemiology Forecast to 2026 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Supportive Care in Oncology – Epidemiology Forecast to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Supportive Care in Oncology – Epidemiology Forecast to 2026 in real time.

  • Access a live EpiCast Report: Supportive Care in Oncology – Epidemiology Forecast to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.